US2016082006A1PendingUtilityA1

Pharmacological treatment of parkinson's disease

46
Individually held — no corporate assignee on recordPriority: Feb 28, 2006Filed: Dec 3, 2015Published: Mar 24, 2016
Est. expiryFeb 28, 2026(expired)· nominal 20-yr term from priority
Inventors:William A. WolfErik D. Istre
A61K 31/496A61K 31/137A61K 31/55A61K 45/06A61K 31/497A61K 31/198A61P 25/16
46
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to the co-administration of two neurotransmitter agonists to patients with motor disorders, for the purpose of symptom reduction. In particular the present invention provides methods and compositions for alleviation of akinesia, rigidity and/or tremor associated with Parkinson's disease.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A method of treating a motor disorder side effect associated with administration of L-DOPA to a subject having Parkinson's disease, wherein said motor disorder side effect is reduced by administering a therapeutic dose of eltoprazine to said subject. 
     
     
         2 . The method according to  claim 1 , wherein said motor disorder side effect is dyskinesia. 
     
     
         3 . The method according to  claim 1 , wherein said L-DOPA is administered at a subtherapeutic dose. 
     
     
         4 . The method according to  claim 1 , wherein said eltoprazine and said L-DOPA are concurrently active in said subject. 
     
     
         5 . The method according to  claim 1 , wherein said eltoprazine is administered to said subject after the development of said motor disorder side effect. 
     
     
         6 . The method according to  claim 1 , wherein said eltoprazine is administered to said subject before the development of said motor disorder side effect. 
     
     
         7 . The method according to  claim 1 , wherein said eltoprazine is administered to said subject before the initiation of L-DOPA administration. 
     
     
         8 . The method according to  claim 1 , wherein after the administration to said subject of said eltoprazine and said L-DOPA, the dose of L-DOPA is reduced. 
     
     
         9 . The method according to  claim 1 , wherein said subject is a human. 
     
     
         10 . A method of treating dyskinesia associated with administration of L-DOPA to a human having Parkinson's disease, wherein said dyskinesia is reduced by administering a therapeutic dose of eltoprazine to said human. 
     
     
         11 . A kit comprising eltoprazine, L-DOPA, and instructions for administering eltoprazine and L-DOPA to a subject having Parkinson's disease. 
     
     
         12 . A method of treating Parkinson's disease in a subject in need thereof, comprising administering a therapeutic dose of L-DOPA and a therapeutic dose of eltoprazine to said subject. 
     
     
         13 . The method according to  claim 12 , wherein said L-DOPA is administered at a subtherapeutic dose. 
     
     
         14 . The method according to  claim 12 , wherein said eltoprazine and said L-DOPA are concurrently active in said subject. 
     
     
         15 . The method according to  claim 12 , wherein said eltoprazine is administered to said subject before said subject develops dyskinesia associated with said L-DOPA administration. 
     
     
         16 . The method according to  claim 12 , wherein said eltoprazine is administered to said subject after said subject develops dyskinesia associated with said L-DOPA administration. 
     
     
         17 . The method according to  claim 12 , wherein said eltoprazine is administered to said subject before the initiation of L-DOPA administration. 
     
     
         18 . The method according to  claim 12 , wherein said L-DOPA is administered to said subject before the initiation of eltoprazine administration. 
     
     
         19 . The method according to  claim 12 , wherein after the administration to said subject of said eltoprazine and said L-DOPA, the dose of L-DOPA is reduced. 
     
     
         20 . The method according to  claim 12 , wherein said subject is a human. 
     
     
         21 . A method of treating Parkinson's disease in a human, comprising administering a therapeutic dose of L-DOPA and a therapeutic dose of eltoprazine to said human.

Join the waitlist — get patent alerts

Track US2016082006A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.